How to Tell If Your IVIG Is Working:Signs of Progress Patients and Caregivers Should Know

Intravenous immunoglobulin (IVIG) therapy is used to treat a broad range of immunodeficiency, autoimmune, and neurological conditions. For patients and caregivers, understanding how to evaluate whether treatment is effective is essential to informed participation in the care process. This article reviews the clinical indicators, laboratory markers, functional outcomes, and patient-reported measures that signal IVIG is working. It draws exclusively on peer-reviewed literature and professional organization guidelines—including those from the Immunoglobulin National Society (IgNS), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the Immune Deficiency Foundation (IDF)—to provide an evidence-based framework for evaluating treatment response. The article is intended for patient education and specialty pharmacy partner audiences.

Keywords: IVIG, immunoglobulin therapy, treatment effectiveness, patient education, IgG trough levels, CIDP, primary immunodeficiency

How to Tell If Your IVIG Is Working:

Signs of Progress Patients and Caregivers Should Know

If you have recently started intravenous immunoglobulin (IVIG) therapy—or have been receiving it for some time—you may be wondering how to tell whether the treatment is actually working. It is a natural and important question. IVIG is used to treat a wide range of conditions, from primary immunodeficiencies to autoimmune and neurological disorders, and the signs of effectiveness can look very different depending on why you are receiving it.

There is no single timeline for improvement. The American Academy of Allergy, Asthma, and Immunology (AAAAI) classifies IVIG indications along a spectrum of expected benefit, ranging from “definitely beneficial” to “unlikely to provide benefit” (as cited in StatPearls; National Center for Biotechnology Information [NCBI], 2023). Some patients notice changes within days, while others require several months of consistent therapy before measurable improvement emerges. What matters most is that you and your healthcare team are looking at the right markers of progress for your specific diagnosis.

This article is designed to help you understand what “working” looks like across the most common IVIG indications, what laboratory values to pay attention to, and how to partner with your care team to get the most out of your therapy.

Fewer and Less Severe Infections

For patients living with primary immunodeficiency (PI), the central goal of IVIG is to replace the antibodies the body cannot produce and protect against recurrent infections. If therapy is working, the most meaningful early sign is typically a reduction in the number, severity, and duration of infections.

What to Look For

Fewer respiratory infections. Conditions such as sinusitis, bronchitis, and pneumonia are among the most common complications of antibody deficiency. After several infusions, many patients notice that these episodes become less frequent or resolve more quickly than they did before treatment.

Reduced need for antibiotics. If a patient previously required multiple courses of oral or intravenous antibiotics each year, a decline in antibiotic use can be a strong indicator that the immune system is receiving the support it needs.

Fewer emergency visits and hospitalizations. Severe or recurrent infections that previously led to urgent care visits or inpatient stays should decrease as protective antibody levels are maintained.

Research supports the relationship between higher immunoglobulin levels and fewer infections. A meta-analysis by Orange et al. (2010) demonstrated that patients with primary immunodeficiency who maintained higher IgG trough levels experienced significantly fewer episodes of pneumonia. Bonagura et al. (2008) further established that higher biologic IgG levels correlated with improved infection prevention. More recently, a 2025 study examining 75 antibody-deficient patients found that those with steady-state IgG levels between 800 and 900 mg/dL averaged three to four infections per year, compared to six infections per year in those with levels around 600 mg/dL (Immune Deficiency Foundation [IDF], 2025).

Laboratory Markers

While how a patient feels day to day is the most important measure of treatment success, laboratory tests provide objective data that helps the care team fine-tune therapy. Understanding these numbers supports informed conversations with providers about dose adjustments and treatment goals.

IgG Trough Levels

The IgG trough level is the most widely used laboratory marker for evaluating the adequacy of IVIG replacement therapy. It represents the lowest concentration of immunoglobulin G in the blood, measured just before the next infusion—the baseline level of protection at its most vulnerable point in the treatment cycle.

Historically, a trough level of 500 mg/dL was considered the minimum protective threshold. However, current evidence supports targeting higher levels, generally in the range of 700 to 1,000 mg/dL, particularly for patients with chronic lung disease or other comorbidities. A 2024 review in Expert Review of Clinical Immunology emphasized that individualized trough targets should be established based on each patient’s unique clinical response, not a one-size-fits-all number. The dosing strategy requires individualization based on serum IgG trough levels, clinical response, and the patient’s past experiences with immunoglobulin therapies (Expert Review of Clinical Immunology, 2024).

Other Relevant Lab Work

Complete blood count (CBC) with differential can reveal trends in white blood cell counts and other immune cell populations that correlate with response to supplemental immunoglobulin.

Inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are particularly relevant for patients receiving IVIG for autoimmune or inflammatory conditions. A downward trend in these values can signal that the immunomodulatory effects of therapy are taking hold.

Disease-specific labs vary by diagnosis. Patients with immune thrombocytopenia will track platelet counts, while patients with myasthenia gravis may monitor acetylcholine receptor antibody levels. The prescriber will determine which labs are appropriate for each condition.

Importantly, trough levels should always be interpreted alongside clinical response—not in isolation. As the IgNS Ig Therapy Standards of Practice (Version 3.2) and the NCBI StatPearls chapter on IVIG both emphasize, clinical response is the most important variable on which to base treatment decisions (NCBI, 2023; IgNS, 2024).

Improvement in Neurological Function

For patients receiving IVIG for neurological conditions—most commonly chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN)—the signs that treatment is working tend to be functional and physical rather than purely laboratory-based. IVIG works as an immunomodulator in these conditions, helping to reduce the immune system’s attack on the myelin sheath that protects peripheral nerves.

Signs of Improvement

Increased grip strength. One of the earliest and most measurable signs of IVIG response in CIDP is improvement in hand grip strength. Research has used daily grip strength measurements as a sensitive marker for tracking treatment-related fluctuations between infusion cycles (Allen et al., 2023).

Improved mobility and balance. Many patients report that walking becomes easier, stairs feel more manageable, and they become less reliant on assistive devices such as canes or walkers. A 2025 real-world effectiveness study found that patients receiving immunoglobulin therapy were approximately 40% less likely to experience worsening in assistive device use compared to matched patients who did not receive treatment (Hubsch et al., 2025).

Reduced numbness, tingling, and weakness. Sensory and motor symptoms may gradually improve as nerve damage stabilizes. While IVIG does not reverse existing nerve damage, it can halt further demyelination and allow the body’s natural repair processes to work.

Less fatigue. Fatigue is one of the most debilitating symptoms reported by CIDP patients. Effective IVIG therapy has been associated with improvements in overall energy levels and the ability to participate in daily activities.

Understanding Treatment-Related Fluctuations

Some patients notice that their symptoms improve after each infusion but begin to return as they approach the next dose. These are known as treatment-related fluctuations (TRFs). Allen et al. (2023) found that approximately half of CIDP patients on IVIG experienced measurable fluctuations in grip strength between infusion cycles. The presence of TRFs can be evidence that IVIG is working—it means the body is responding to the therapy, and the care team may need to adjust the dose or frequency to maintain a more consistent level of function.

A landmark placebo-controlled crossover trial by Hahn et al. (1996) demonstrated that 63% of CIDP patients improved with IVIG, with statistically significant gains in neurological disability scores, clinical grade, and grip strength compared to placebo. More recently, a 2025 mixed-methods study reported that 69% of patients perceived substantial improvements in physical function, including renewed strength, restored walking ability, and reduced pain (PMC, 2025).

Reduction in Autoimmune Flares and Inflammatory Symptoms

When IVIG is prescribed for autoimmune and inflammatory conditions—such as myasthenia gravis, immune thrombocytopenia, autoimmune hemolytic anemia, or stiff-person syndrome—it is typically administered at higher immunomodulatory doses. In these contexts, the treatment works not by replacing missing antibodies, but by regulating an overactive immune system.

What to Look For

Fewer disease flare-ups. A sustained reduction in the frequency and intensity of flares is one of the most reliable indicators that immunomodulatory IVIG is effective. This may manifest as fewer episodes of muscle weakness in myasthenia gravis, stabilization of platelet counts in immune thrombocytopenia, or reduced stiffness and spasms in stiff-person syndrome.

Decreased reliance on corticosteroids. Many patients are started on IVIG with the goal of reducing or eliminating the need for long-term corticosteroid use. If a prescriber has been able to taper prednisone or other immunosuppressant medications while symptoms remain stable, that is a meaningful sign that IVIG is providing the intended immunomodulatory benefit.

Sustained stability on maintenance therapy. For chronic conditions, the goal is often long-term disease control. Dalakas et al. (2022) examined 36 patients with stiff-person syndrome and demonstrated that two-thirds achieved clinically significant, sustained benefit on long-term IVIG maintenance therapy. Symptom recurrence upon dose reduction confirmed ongoing therapeutic need.

Improved Quality of Life

While laboratory results and clinical scales are valuable tools, the improvements that matter most to patients are often the ones that show up in daily life. Increasingly, clinical research and professional organizations recognize that patient-reported outcomes (PROs) are essential to evaluating the true effectiveness of IVIG therapy.

Everyday Signs of Progress

Patients do not need a lab report to notice that they are sleeping better, getting through the workday without overwhelming fatigue, playing with their children again, or walking to the mailbox without assistance. These functional gains are exactly the kinds of improvements that validated quality-of-life instruments—such as the SF-36 Physical Component Summary, the EuroQoL Visual Analogue Scale, and the Treatment Satisfaction Questionnaire for Medication (TSQM-9)—are designed to capture.

Data from the ADVANCE-CIDP IVIG trial showed that patients experienced maintained or meaningfully improved quality-of-life scores during IVIG treatment, with overall treatment satisfaction scores averaging approximately 70 out of 100 for global satisfaction and nearly 69 for perceived effectiveness (Pasnoor et al., 2025). While these may seem like abstract numbers, they reflect real patients reporting that therapy made a tangible difference in how they felt and functioned.

Practical Milestones to Track

Patients are encouraged to keep a simple record of milestones that are personally meaningful. Examples might include returning to work or school, resuming a hobby, driving again, reducing the use of a walker or cane, completing household tasks independently, or attending social events that had been avoided. These personal benchmarks, when shared with the care team, provide valuable context that complements what laboratory values show.

What to Do If You Are Not Sure It Is Working

Uncertainty about whether treatment is effective is completely normal, and it is a conversation patients should never hesitate to have with their care team.

Keep a Symptom Diary

Tracking symptoms, energy levels, infections, and functional milestones between infusions can reveal patterns that might otherwise be difficult to see. Even a brief daily note—a few words about how the day felt, what was accomplished, or any new symptoms—can be enormously helpful when sitting down with a provider.

Communicate With Your Infusion Nurse

The infusion nurse sees patients at a consistent interval and is trained to observe changes over time—shifts in vital signs, functional capacity, and overall well-being. Patients should not wait for a scheduled provider appointment to share concerns. The infusion nurse is an important advocate and conduit of information to the broader care team.

Understand the Wear-Off Effect

It is not uncommon for patients to feel a dip in symptom control in the days leading up to their next infusion. This end-of-cycle wear-off effect is well documented and may simply mean that the dose, frequency, or route of administration (IVIG versus subcutaneous immunoglobulin) needs to be adjusted. This is a clinical optimization conversation, not a sign of treatment failure (NCBI, 2023).

Know When to Request a Reassessment

If a patient continues to experience frequent infections despite adequate IgG trough levels, sees no functional improvement after three to six months of consistent therapy, or notices worsening symptoms, it may be time for the prescriber to reevaluate the diagnosis, dose, or treatment approach. IVIG is not effective for all conditions, and the foundation of successful therapy is an accurate diagnosis. The AAAAI’s guiding principles for IVIG use emphasize that clinical response—not laboratory values alone—is the most important variable on which to base treatment decisions (AAAAI, n.d.).

The Role of the Infusion Care Team

IVIG therapy is one of the most complex treatments in clinical use today, and the quality of outcomes is closely tied to the expertise of the team delivering care. The Immunoglobulin National Society (IgNS) Standards of Practice emphasize that safe, effective immunoglobulin therapy requires a multidisciplinary approach—bringing together prescribers, specialty pharmacists, and infusion nurses who work as a coordinated team (IgNS, 2024).

The infusion nurse plays a uniquely important role in monitoring treatment response. Unlike a quarterly office visit, infusion appointments occur on a regular cycle—often every three to four weeks—giving the nurse a consistent window into functional status, vital sign trends, side effect patterns, and overall well-being. Specialty-trained infusion nurses, particularly those holding the IgNS Immunoglobulin Certified Nurse (IgCN) credential, possess specific expertise in recognizing subtle signs of treatment response or decline that can make a meaningful difference in optimizing therapy (IgNS, 2024).

Patients should feel empowered to ask questions, share concerns, and participate actively in decisions about their treatment plan. The concept of shared decision-making—where the patient’s preferences, values, and lived experience carry weight alongside clinical data—is embedded in the IgNS standards and is a hallmark of high-quality immunoglobulin therapy.

Conclusion

IVIG therapy is deeply individualized. What “working” looks like for a patient with primary immunodeficiency will be different from what it looks like for a patient with CIDP, stiff-person syndrome, or another autoimmune condition. The strongest evidence for effectiveness comes from combining three complementary perspectives: objective laboratory data, validated clinical outcome measures, and the patient’s own reported experience.

Progress may be dramatic and rapid, or it may be gradual and subtle. Either way, it is measurable—if the patient and the care team know what to look for. Every patient is encouraged to be an active participant in their therapy: keep a symptom diary, ask about lab results, communicate openly with the infusion nurse, and never hesitate to advocate when something does not feel right.

The care team is a partner in this journey. Together, patients and clinicians have the tools and the knowledge to evaluate whether IVIG is making a difference—and to adjust course when it is needed.

References

Allen, J. A., Pasnoor, M., Engel, D., & Dua, A. (2023). CIDP prognosis in patients with IVIG treatment-related fluctuations. Muscle & Nerve, 68(2), 201–207. https://doi.org/10.1002/mus.27893

American Academy of Allergy, Asthma, and Immunology. (n.d.). Guiding principles for effective use of IVIG for patients with primary immunodeficiency. https://www.aaaai.org

Bonagura, V. R., Marchlewski, R., Cox, A., & Rosenthal, D. W. (2008). Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection. Journal of Allergy and Clinical Immunology, 122(1), 210–212. https://doi.org/10.1016/j.jaci.2008.04.044

Dalakas, M. C., Rakocevic, G., Dambrosia, J. M., Alexopoulos, H., & McElroy, B. (2022). Long-term effectiveness of IVIg maintenance therapy in 36 patients with GAD antibody–positive stiff-person syndrome. Neurology: Neuroimmunology & Neuroinflammation, 9(5), e200011. https://doi.org/10.1212/NXI.0000000000200011

Expert Review of Clinical Immunology. (2024). Immunoglobulin therapies for primary immunodeficiency diseases (Part 2): Considerations for dosing strategies. Expert Review of Clinical Immunology, 20(10). https://doi.org/10.1080/1750743X.2024.2382074

Hahn, A. F., Bolton, C. F., Zochodne, D., & Feasby, T. E. (1996). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study. Brain, 119(4), 1067–1077. https://doi.org/10.1093/brain/119.4.1067

Hubsch, A., Divino, V., Mallick, R., DeKoven, M., Engel, T., Engmann, N. J., & Basta, M. (2025). An evaluation of the real-world effectiveness of immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Neurology and Therapy. https://doi.org/10.1007/s40120-025-00691-6

Immune Deficiency Foundation. (2025). Consider increasing Ig therapy for breakthrough infections. https://primaryimmune.org/resources/news-articles/consider-increasing-ig-therapy-breakthrough-infections

Immune Deficiency Foundation. (n.d.). Immunoglobulin replacement therapy. https://primaryimmune.org/understanding-primary-immunodeficiency/treatment/immunoglobulin-replacement-therapy

Immunoglobulin National Society. (2024). Ig therapy standards of practice (Version 3.2). https://ig-ns.org/standards-and-guides/

Immunoglobulin National Society. (2024). Patient guide to immunoglobulin therapy. https://ig-ns.org/product/patient-guide/

Lee, J. L., Mohamed Shah, N., Makmor-Bakry, M., Islahudin, F., Alias, H., Noh, L. M., & Syed-Abdul-Rahman, S. A. (2020). A systematic review and meta-regression analysis on the impact of increasing IgG trough level on infection rates in primary immunodeficiency patients on intravenous IgG therapy. Journal of Clinical Immunology, 40(5), 682–698. https://doi.org/10.1007/s10875-020-00788-5

National Center for Biotechnology Information. (2023). Intravenous immunoglobulin (IVIG). In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554446/

Orange, J. S., Grossman, W. J., Navickis, R. J., & Wilkes, M. M. (2010). Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clinical Immunology, 137(1), 21–30. https://doi.org/10.1016/j.clim.2010.06.012

Pasnoor, M., Anderson-Smits, C., Levine, T., Bril, V., Solano, J. M., Rejdak, K., & Gamez, J. (2025). The results of ADVANCE-CIDP IVIG trial: Intravenous immunoglobulin 10% therapy for treatment of relapse in CIDP. Muscle & Nerve. https://doi.org/10.1002/mus.28377

Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., ... & Ballow, M. (2017). Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 139(3S), S1–S46. https://doi.org/10.1016/j.jaci.2016.09.023

PMC. (2025). Experiences of immunoglobulin therapy for those with a confirmed diagnosis of chronic inflammatory demyelinating polyneuropathy: A mixed-methods study with a qualitative patient perspective focus. PubMed Central.

Shrestha, P., Karmacharya, P., Wang, Z., Donato, A., & Joshi, A. Y. (2019). Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. World Allergy Organization Journal, 12(10), 100068. https://doi.org/10.1016/j.waojou.2019.100068